22 April 2025FeaturesEuropeAdam Gregory, Mewburn Ellis

In vivo cell therapy: A world beyond ex vivo engineering

For those willing to undertake the complexity, in vivo cell therapy could redefine the economics and logistics of cell-based treatment, says Adam Gregory of Mewburn Ellis.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug

Patent litigator with biotech and medical device background joins Sterlington

How pharma should prep for the six-bill avalanche from Congress

USPTO speeds up patent issuance amid widespread agency changes

Lathrop GPM adds portfolio management specialist

Failure to make findings of fact adds twist to battle over Eliquis in Ireland

Patent pledges in global crises: Why Moderna prevailed over Pfizer/BioNTech

EPO: Biotech innovation strong, while pharma trails behind

In vivo cell therapy: A world beyond ex vivo engineering

Editor's picks

Editor's picks

More features